

stipend authorized to be paid to the members for performance of their official duties. However, Committee members will be authorized to receive per diem and reimbursement for travel expenses incurred for attending public meetings.

**Structure:** It is proposed that the Committee will consist of 11–17 members; one or two members will be selected to serve as the Chair, Vice Chair, and/or Co-Chairs. To be eligible for consideration of appointment to the Committee, individuals should be knowledgeable of current scientific research in human physical activity and be respected and published experts in their fields. They should be familiar with the purpose, communication, and application of federal physical activity guidelines and have demonstrated interest in the public's health and well-being through their research and/or educational endeavors. Expertise is sought in specific specialty areas related to physical activity and health promotion or disease prevention, including but not limited to: Health promotion and chronic disease prevention; bone, joint, and muscle health and performance; obesity and weight management; physical activity and risk of musculoskeletal injury; physical activity and cognition; physical activity within specific settings, such as preschool/childcare, schools (*e.g.*, activity breaks, physical education), or the community/built environment; physical activity dose-response; sedentary behavior; behavior change; systematic reviews; and special populations including children, older adults, individuals with disabilities, or women who are pregnant.

**Nominations:** HHS will consider nominations, including self-nominations, for Committee membership of individuals qualified to carry out the above-mentioned tasks. The following information should be included in the package of material submitted for each individual being nominated for consideration: (1) The name, address, daytime telephone number, and email address of the nominator and the individual being nominated; (2) a letter of nomination that clearly states the name and affiliation of the nominee, the basis for the nomination (*i.e.*, specific attributes which qualify the nominee for service in this capacity), and a statement from the nominee that the nominee is willing to serve as a member of the Committee; and (3) a current copy of the nominee's curriculum vitae (CV) no more than 10 pages in length. Inclusion of the following is requested in the CV: (1) Current and/or past grant awards; (2)

publications showing both breadth and experience in areas of specialization; (3) paid and non-paid board and advisory appointments; and (4) education and occupational history.

All nominations must include the required information. Incomplete nominations will not be processed for consideration. Federal employees should not be nominated for consideration of appointment to this Committee.

Equal opportunity practices regarding membership appointments to the Committee will be aligned with HHS policies. When possible, every effort will be made to ensure that the Committee is a diverse group of individuals with representation from various geographic locations, racial and ethnic minorities, all genders, and persons with disabilities. Individuals will be appointed to serve as members of the Committee to represent balanced viewpoints of the scientific evidence, not to represent the viewpoints of any specific group.

Members of the Committee will be classified as special government employees (SGEs) during their term of appointment to the Committee, and as such are subject to the ethical standards of conduct for federal employees. Upon entering the position and annually throughout the term of appointment, members of the Committee will be required to complete and submit a report of their financial holdings, consultancies, and research grants and/or contracts. The purpose of this report is to determine if the individual has any interest and/or activities in the private sector that may conflict with performance of their official duties as a member of the Committee.

Dated: December 15, 2015.

**Don Wright,**

*Deputy Assistant Secretary for Health, Office of Disease Prevention and Health Promotion.*

[FR Doc. 2015–31837 Filed 12–17–15; 8:45 am]

**BILLING CODE 4150–32–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Nursing Research; Notice of Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Council for Nursing Research.

The meeting will be open to the public as indicated below, with

attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Advisory Council for Nursing Research.

**Date:** January 26–27, 2016.

**Open:** January 26, 2016, 1:00 p.m. to 4:45 p.m.

**Agenda:** Discussion of Program Policies and Issues.

**Place:** National Institutes of Health, Porter Neuroscience Research Center, Building 35A, Convent Drive, Room 620/630, Bethesda, MD 20892.

**Closed:** January 27, 2016, 9:00 a.m. to 1:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, Porter Neuroscience Research Center, Building 35A, Convent Drive, Room 620/630, Bethesda, MD 20892.

**Contact Person:** Ann R. Knebel, DNSC, RN, FAAN, Deputy Director, National Institute of Nursing Research, National Institutes of Health, 31 Center Drive, Building 31, Room 5B05, Bethesda, MD 20892, 301–496–8230, [knebelar@mail.nih.gov](mailto:knebelar@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: [www.nih.gov/ninr/aadvisory.html](http://www.nih.gov/ninr/aadvisory.html), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.361, Nursing Research, National Institutes of Health, HHS)

Dated: December 14, 2015.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015-31768 Filed 12-17-15; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Interagency Coordinating Committee on the Validation of Alternative Methods Communities of Practice Webinar on Fundamentals of Using Quantitative Structure-Activity Relationship Models and Read-across Techniques in Predictive Toxicology; Notice of Public Webinar; Registration Information

**SUMMARY:** The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) announces a public webinar “Fundamentals of Using Quantitative Structure-Activity Relationship Models and Read-Across Techniques in Predictive Toxicology.” The webinar is organized on behalf of ICCVAM by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and hosted by the U.S. Environmental Protection Agency’s (EPA’s) National Center for Computational Toxicology (NCCT). Interested persons may participate via Adobe® Connect™. Time is allotted for questions from the audience.

**DATES:** *Webinar:* January 26, 2016, 1 p.m. to approximately 2:30 p.m. Eastern Standard Time (EST).

Registration for Webinar: December 18, 2015 until January 26, 2016 at 2:30 p.m.

**ADDRESSES:** Webinar Web page: <http://ntp.niehs.nih.gov/go/commprac-2016>.

**FOR FURTHER INFORMATION CONTACT:** Dr. Warren S. Casey, Director, NICEATM; email: [warren.casey@nih.gov](mailto:warren.casey@nih.gov); telephone: (919) 316-4729.

#### **SUPPLEMENTARY INFORMATION:**

*Background:* ICCVAM promotes the development and validation of toxicity testing methods that protect human health and the environment while replacing, reducing, or refining animal use. ICCVAM also provides guidance to test method developers and facilitates collaborations that promote the development of new test methods. To address these goals, ICCVAM is organizing a webinar on “Fundamentals of Using Quantitative Structure-Activity Relationship Models and Read-

across Techniques in Predictive Toxicology.”

Many commercial and environmental chemicals lack toxicity data necessary for users and risk assessors to make informed decisions about their potential health effects. Computational methods use data about structure, properties, and toxicity from tested chemicals to make predictions about the characteristics of untested chemicals. These include quantitative structure-activity relationship (QSAR) models, which predict the activities of chemicals with unknown properties by relating them to properties of known chemicals, and read-across, which uses toxicity data from a known (source) chemical to predict toxicity for another (target) chemical, usually but not always on the basis of structural similarity. Predictions made using these methods about toxicity of untested chemicals can help set priorities for future *in vitro* or *in vivo* testing, ensuring that the most important hazards are characterized first and that testing resources are used efficiently.

The ICCVAM webinar will feature presentations by two experts in the development and application of QSAR models and read-across techniques. Alex Tropsha, Ph.D., associate dean for pharmacoinformatics and data science at the University of North Carolina at Chapel Hill, will discuss fundamentals of QSAR models. Louis (Gino) Scarano, Ph.D., of the EPA’s Office of Pollution Prevention and Toxics, will describe read-across techniques and discuss the regulatory applications of QSAR models and read-across techniques.

*Webinar and Registration:* This webinar is open to the public with time scheduled for questions by attendees following each presentation. Registration for the webinar is required and is open from December 18, 2015, through 2:30 p.m. on January 26, 2016. A link to registration is available at <http://ntp.niehs.nih.gov/go/commprac-2016>. Registrants will receive instructions on how to access and participate in the webinar in the email confirming their registration.

The preliminary agenda is available at <http://ntp.niehs.nih.gov/go/commprac-2016>. Interested individuals are encouraged to visit this Web page to stay abreast of the most current webinar information.

Individuals with disabilities who need accommodation to participate in this event should contact Ms. LaCresha Styles at phone: (919) 541-3282 or email: [styles.lacresha@epa.gov](mailto:styles.lacresha@epa.gov). TTY users should contact the Federal TTY Relay Service at (800) 877-8339.

Requests should be made at least five business days in advance of the event.

*Background Information on ICCVAM and NICEATM:* ICCVAM is an interagency committee composed of representatives from 15 federal regulatory and research agencies that require, use, generate, or disseminate toxicological and safety testing information. The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l-3) establishes ICCVAM as a permanent interagency committee of the National Institute of Environmental Health Sciences and provides the authority for ICCVAM’s involvement in activities relevant to the development of new and revised toxicological tests.

ICCVAM conducts technical evaluations of new, revised, and alternative test methods and testing strategies with regulatory applicability and promotes the scientific validation and regulatory acceptance of test methods that both more accurately assess the safety and hazards of chemicals and products and replace, reduce, or refine (enhance animal well-being and lessen or avoid pain and distress) animal use. ICCVAM acts to ensure that new and revised test methods are validated to meet the needs of federal agencies, to increase the efficiency and effectiveness of federal agency test method review, and to optimize utilization of scientific expertise outside the federal government. Additional information about ICCVAM can be found at <http://ntp.niehs.nih.gov/go/iccvam>.

NICEATM administers ICCVAM, provides scientific and operational support for ICCVAM activities, and conducts analyses and evaluations and coordinates independent validation studies on novel and high-priority alternative testing approaches. NICEATM and ICCVAM work collaboratively to evaluate new and improved test methods and strategies applicable to the needs of U.S. federal agencies. NICEATM and ICCVAM welcome the public nomination of new, revised, and alternative test methods and strategies for validation studies and technical evaluations. Additional information about NICEATM can be found at <http://ntp.niehs.nih.gov/go/niceatm>.

Dated: December 15, 2015.

**John R. Bucher,**

*Associate Director, National Toxicology Program.*

[FR Doc. 2015-31832 Filed 12-17-15; 8:45 am]

**BILLING CODE 4140-01-P**